Here, we specifically focused on HER2+ breast cancer cells based on our previous studies demonstrating the pathogenesis of this cancer subtype responsive to dysregulated NO levels and their great sensitivity to SEP treatment (21, 22, 54). The gene discussed is ERBB2; the disease is cancer.